Qube Research & Technologies (QRT)
KALV

Qube Research & Technologies (QRT)’s KalVista Pharmaceuticals KALV Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.63M Buy
+180,314
New +$2.91M ﹤0.01% 1828
2025
Q4 		– Sell
-325,435
Closed -$3.96M – 3883
2025
Q3 		$3.96M Buy
325,435
+228,187
+235% +$3.15M ﹤0.01% 1894
2025
Q2 		$1.1M Buy
+97,248
New +$1.19M ﹤0.01% 2425
2025
Q1 		– Sell
-126,132
Closed -$1.07M – 3696
2024
Q4 		$1.07M Sell
126,132
-52,476
-29% -$543K ﹤0.01% 2139
2024
Q3 		$2.07M Buy
178,608
+149,019
+504% +$1.87M ﹤0.01% 1752
2024
Q2 		$349K Sell
29,589
-149,149
-83% -$1.74M ﹤0.01% 2259
2024
Q1 		$2.12M Buy
+178,738
New +$2.38M ﹤0.01% 1720
2021
Q2 		– Sell
-21,030
Closed -$540K – 2541
2021
Q1 		$540K Buy
+21,030
New +$553K 0.01% 1135

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Qube Research & Technologies (QRT)'s KALV Position: Q1 2026 in Review

Qube Research & Technologies (QRT) opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 180,314 shares worth $3.63M. The stake represents ﹤0.01% of the portfolio and ranks #1828 among its holdings. This is a return to the name: Qube Research & Technologies (QRT) previously reported a position in KALV as recently as Q3 2025.

Qube Research & Technologies (QRT) first reported a position in KALV in Q1 2021 and has held it in 8 quarters since. The position peaked at $3.96M in Q3 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Qube Research & Technologies (QRT) held 180,314 shares of KalVista Pharmaceuticals worth $3.63M as of Q1 2026.
  • KalVista Pharmaceuticals was a new Qube Research & Technologies (QRT) position in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #1828 holding.
  • Qube Research & Technologies (QRT) first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 8 quarters since.
  • Qube Research & Technologies (QRT)'s KalVista Pharmaceuticals position peaked at $3.96M in Q3 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.